Arcadia Biosciences, Inc. (RKDA) Form 8-K — Sep 15, 2026
Stockholders of Arcadia Biosciences (RKDA) approved at the September 10, 2026 annual meeting a charter amendment authorizing a reverse stock split at a ratio ranging from 1-for-2 to 1-for-10, to be effected at the Board's discretion at any time before June 30, 2027. An authorization of this range typically signals pressure to cure sub-$1.00 share prices and maintain exchange listing compliance. Shareholders also approved the potential issuance of common stock upon exercise of the Series A-1 Preferred Investment Options issued in the company's private placement that closed June 12, 2026.
Key figures
- Reverse Split Deadline
- June 30, 2027
- Reverse Split Ratio Range
- 1-for-2 to 1-for-10
- Shares Present At Meeting
- 1259315
- Equity Plan Annual Increase
- lesser of 4% of outstanding shares or Board-determined amount
- Equity Plan Iso Limit Shares
- 4000000
- Implied Shares Outstanding
- approximately 2.4 million (derived from 1,259,315 shares representing 52.3% of outstanding)
- Series A1 Placement Close Date
- June 12, 2026
- Percent Of Outstanding Present
- 52.3%
- Equity Plan Initial Share Reserve
- 400000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.